Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 4/20 | 0.40 |
| ▸ | BCL9 | O00512 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 3/20 | 0.37 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17535540 | 0.81 | OPRK1 (0.37) | MAPTKDM4EALDH1A1 | |
| SCHEMBL15456939 | 0.81 | PTGER4 (0.39) | MAPTKMT2AMEN1HRH3SIRT6 | |
| SCHEMBL17535415 | 0.80 | NR1I2 (0.35) | MAPTKDM4EALDH1A1HRH3GAA | |
| SCHEMBL10145139 | 0.80 | GAA (0.45) | MAPTKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL16056050 | 0.80 | HIF1A (0.46) | HIF1AMAPTKDM4EALDH1A1HTT | |
| SCHEMBL24107480 | 0.78 | HRH3 (0.60) | KMT2AHRH3 | |
| SCHEMBL20976848 | 0.77 | HIF1A (0.60) | HIF1AMAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL15398592 | 0.77 | PTGER4 (0.36) | HRH3PLK1 | |
| SCHEMBL12316369 | 0.76 | HIF1A (0.62) | HIF1AMAPTKDM4EALDH1A1HTT | |
| SCHEMBL30263167 | 0.76 | HIF1A (0.62) | HIF1AMAPTKDM4EALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970331-B1 | SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-17 | — | — | EP | disclosed |
| US-9605000-B2 | Spiro azetidine isoxazole derivatives and their use as SSTR antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-28 | — | — | US | disclosed |
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR1, SSTR2 | HIF1A 1757/4885BCL9 3067/4885CTNNB1 2197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.